NAGE ChromaDex: Company Value to Revenue

Official company branding of ChromaDex (NAGE)

The EV/Sales chart illustrates the business value-to-revenue dynamics, where the 659.66 mark indicates the current state. Growth in Niagen sales and the expansion of partnerships within the dietary supplement sector are driving the current momentum for Chromadex Corp (NAGE). Simultaneously, the company is implementing ESG standards by minimizing plastic use and conserving resources. Supply chain stability is ensured through in-house laboratories and rigorous quality control of precision components.

niagenbioscience.com (NAGE): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

NAGE (ChromaDex Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:Chromadex Corp
Manufactured products of ChromaDex Corp.

This ratio determines the market value of the business relative to sales volume, excluding the impact of debt load. The calculation combines market capitalization and net debt, allowing for an assessment of the real price per unit of revenue. By analyzing the EV/Sales history, an investor identifies whether an asset is overvalued or possesses growth potential. For Chromadex Corp (NAGE), this is critical when scaling Niagen sales through global partners. The metric demonstrates how much the market is willing to pay for the company's leadership in the NAD+ booster segment.

Competitor analysis for Chromadex Corp

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|Company Value to Revenue ZimVie Inc. ZIMV|EV/Sales Multiple ANGO (angiodynamics.com)|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple